Proposal to fund NovoRapid FlexPen (insulin aspart)
PHARMAC is seeking feedback on a proposal to list insulin aspart (NovoRapid FlexPen) in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 December 2014 through a provisional agreement with Novo Nordisk Pharmaceuticals Limited.
In summary, from 1 December 2014, insulin aspart (NovoRapid FlexPen) would be listed in the community and DHB hospitals at the same price and subsidy as the currently listed presentations of insulin aspart.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Monday, 20 October 2014 to:
Senior Therapeutic Group Manager
PO Box 10 254
Fax: 04 460 4995
All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld. PHARMAC will give due consideration to any such request.
Details of the proposal
NovoRapid FlexPen (insulin aspart) would be listed in Section B and Part II of Section H of the Pharmaceutical Schedule at the following price and subsidy from 1 December 2014 (ex-manufacturer, excluding GST):
|Chemical||Presentation||Brand||Pack size||Price and subsidy|
|Insulin aspart||Inj 100 units per ml, 3 ml||NovoRapid FlexPen||5||$51.19|
NovoRapid FlexPen would have the same certified exception requirement as the other presentations of insulin aspart so it could be dispensed in a three-month lot.